Johnson & Johnson Price to Sales Ratio 2010-2022 | JNJ

Historical PS ratio values for Johnson & Johnson (JNJ) over the last 10 years. The current P/S ratio for Johnson & Johnson as of January 27, 2023 is . For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Johnson & Johnson P/S Ratio Historical Data
Date Stock Price TTM Sales per Share Price to Sales Ratio
2023-01-27 168.23 4.72
2022-12-31 176.65 $35.67 4.95
2022-09-30 162.32 $36.00 4.51
2022-06-30 175.20 $35.79 4.90
2022-03-31 173.83 $35.51 4.89
2021-12-31 166.70 $35.14 4.74
2021-09-30 156.34 $33.76 4.63
2021-06-30 158.53 $31.92 4.97
2020-12-31 149.58 $30.94 4.83
2020-09-30 140.51 $30.25 4.64
2020-06-30 131.85 $30.12 4.38
2020-03-31 122.09 $30.88 3.95
2019-12-31 134.94 $30.55 4.42
2019-09-30 118.86 $30.30 3.92
2019-06-30 127.95 $29.99 4.27
2019-03-31 127.55 $30.01 4.25
2018-12-31 116.98 $29.91 3.91
2018-09-30 124.45 $29.79 4.18
2018-06-30 108.57 $29.51 3.68
2018-03-31 113.82 $28.73 3.96
2017-12-31 123.31 $27.86 4.43
2017-09-30 114.05 $26.99 4.23
2017-06-30 115.31 $26.21 4.40
2017-03-31 107.85 $25.95 4.16
2016-12-31 99.12 $25.74 3.85
2016-09-30 100.93 $25.58 3.95
2016-06-30 102.95 $27.53 3.74
2016-03-31 91.19 $27.01 3.38
2015-12-31 85.95 $27.10 3.17
2021-03-31 157.18 $26.92 5.84
2015-09-30 77.54 $24.94 3.11
2015-06-30 80.33 $25.29 3.18
2015-03-31 82.31 $25.75 3.20
2014-12-31 84.97 $25.91 3.28
2014-09-30 86.05 $25.91 3.32
2014-06-30 83.89 $25.56 3.28
2014-03-31 78.22 $24.96 3.13
2013-12-31 72.41 $24.78 2.92
2013-09-30 68.07 $24.65 2.76
2013-06-30 66.92 $24.60 2.72
2013-03-31 63.06 $24.30 2.59
2012-12-31 53.79 $24.00 2.24
2012-09-30 52.42 $23.61 2.22
2012-06-30 50.93 $23.32 2.18
2012-03-31 49.25 $23.40 2.10
2011-12-31 48.54 $23.42 2.07
2011-09-30 46.70 $23.17 2.02
2011-06-30 48.35 $22.79 2.12
2011-03-31 42.70 $22.30 1.91
2010-12-31 44.17 $22.06 2.00
2010-09-30 43.87 $22.38 1.96
2010-06-30 41.43 $22.40 1.85
2010-03-31 45.32 $22.40 2.02
2009-12-31 44.43 $22.20 2.00
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $441.560B $94.943B
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $330.671B 41.73
Novo Nordisk (NVO) Denmark $311.249B 40.81
Merck (MRK) United States $270.958B 13.95
AbbVie (ABBV) United States $260.674B 10.81
Pfizer (PFE) United States $248.389B 6.79
Novartis AG (NVS) Switzerland $198.780B 14.97